LivaNova LIVN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net revenue by Business | |||||
| Cardiopulmonary | $785.39M+14.9% | $683.51M+13.1% | $604.11M+17.5% | $514.2M+6.5% | |
| Neuromodulation | $592.81M+7.0% | $554.22M+6.6% | $519.71M+9.0% | $476.99M+4.6% | |
| Net revenue by Geography | |||||
| Europe | $269.18M+22.3% | $220.03M+2.4% | $214.79M+20.1% | $178.8M-11.3% | |
| Rest of World | $379.3M+12.1% | $338.32M+11.4% | $303.71M+11.9% | $271.45M+3.4% | |
| United States | $739.57M+6.4% | $695.08M+9.5% | $635.04M+11.1% | $571.56M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.